CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

Bengaluru-based biotechnology startup, CrisprBits Private Limited, has inaugurated a CRISPR gene editing and diagnostics ...

"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...

Our writer thinks these two speculative shares offer high long-term growth potential from where they currently sit in the ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

But, no matter what direction the general market takes, some stocks could stand out, potentially in 2025, and most ...

ErlySign’s innovation is a biomarker-based test kit capable of detecting oral precancerous conditions within just 15 minutes ...

Recent TAU study demonstrates how a crucial but underexplored process of DNA transfer between bacteria affects its defense ...

Colossal Biosciences wants to bring back the woolly mammoth and has raised $200 million at a $10.2 billion valuation to do it ...

Infertility is a major global challenge associated with physiological and psychological impact. Genetic mutations that affect early embryonic ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on RAPT Therapeutics (RAPT – Research Report), GE ...

To prepare students for the challenges and opportunities of an increasingly AI-driven world, Connecticut College has launched ...